Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. by Zhang, XQ et al.
Title Protein alterations associated with temozolomide resistance insubclones of human glioblastoma cell lines.
Author(s) Sun, S; Wong, TS; Zhang, XQ; Pu, JK; Lee, NP; Day, PJ; Ng, GK;Lui, WM; Leung, GK
Citation Journal Of Neuro-Oncology, 2012, v. 107 n. 1, p. 89-100
Issued Date 2012
URL http://hdl.handle.net/10722/144940
Rights The Author(s)
LABORATORY INVESTIGATION - HUMAN/ANIMAL TISSUE
Protein alterations associated with temozolomide resistance
in subclones of human glioblastoma cell lines
Stella Sun • T. S. Wong • X. Q. Zhang •
Jenny K. S. Pu • Nikki P. Lee • Philip J. R. Day •
Gloria K. B. Ng • W. M. Lui • Gilberto K. K. Leung
Received: 23 April 2011 / Accepted: 19 September 2011 / Published online: 7 October 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Temozolomide (TMZ) is the standard chemo-
therapeutic agent for human malignant glioma, but intrinsic
or acquired chemoresistance represents a major obstacle to
successful treatment of this highly lethal group of tumours.
Obtaining better understanding of the molecular mecha-
nisms underlying TMZ resistance in malignant glioma is
important for the development of better treatment strate-
gies. We have successfully established a passage control
line (D54-C10) and resistant variants (D54-P5 and D54-
P10) from the parental TMZ-sensitive malignant glioma
cell line D54-C0. The resistant sub-cell lines showed
alterations in cell morphology, enhanced cell adhesion,
increased migration capacities, and cell cycle arrests. Pro-
teomic analysis identified a set of proteins that showed
gradual changes in expression according to their 50%
inhibitory concentration (IC50). Successful validation was
provided by transcript profiling in another malignant glioma
cell line U87-MG and its resistant counterparts. Moreover,
three of the identified proteins (vimentin, cathepsin D and
prolyl 4-hydroxylase, beta polypeptide) were confirmed to
be upregulated in high-grade glioma. Our data suggest that
acquired TMZ resistance in human malignant glioma is
associated with promotion of malignant phenotypes, and
our reported molecular candidates may serve not only as
markers of chemoresistance but also as potential therapeutic
targets in the treatment of TMZ-resistant human malignant
glioma, providing a platform for future investigations.
Keywords Chemoresistance  Glioma  Proteomics 
Temozolomide  Two-dimensional gel electrophoresis
Introduction
Malignant gliomas are the most common type of primary
brain tumours, and represent one of the most aggressive and
lethal malignancies in adults [1]. The standard treatment of
malignant glioma is multimodal, involving maximal surgical
resection followed by concurrent radiation and chemother-
apy using temozolomide (TMZ). Although this treatment
combination has been shown to prolong survival, the prog-
nosis of patients remains dismal with median survival time of
just over 12 months [2]. Chemotherapeutics play an impor-
tant role in the treatment of malignant glioma [3]. However,
many patients continue to suffer from recurrent diseases due
to de novo or acquired resistance against TMZ [4, 5].
The alkylating agent TMZ is currently the standard
chemotherapeutic for newly diagnosed malignant gliomas
[6]. It is well tolerated and has been shown to provide
significant clinical benefits [7, 8]. Its major action is
mediated through the induction of O6-G methylation,
causing DNA damage which activates the mismatch repair
mechanism. The latter then recognises a recurring error and
triggers apoptosis [9, 10]. However, resistance to TMZ
may occur due to the involvement of both intrinsic or
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acquired pathways [11, 12], and the presence of the blood–
brain barrier, which impedes drug delivery [13]. Epigenetic
modifications are frequently observed in innate chemore-
sistance in gliomas, such as the presence of high level of a
DNA repair enzyme, O6-methylguanine methyltransferase
(MGMT), that removes the methyl adducts and antagonizes
the effects of TMZ [10]. Other mechanisms, including
deficiency of the mismatch repair capacity [11] and robust
base excision repair [14], have also been shown to confer
innate resistance to TMZ. Furthermore, some tumours may
display TMZ resistance that is independent of their MGMT
levels or mismatch repair efficacy, suggesting that other
unknown mechanisms could be involved.
Clinically, acquired TMZ resistance is a significant prob-
lem, with more than 90% of recurrent gliomas showing no
response to repeated challenges with TMZ [15]. Some of the
mechanisms that confer TMZ resistance include selection of
pre-existing TMZ-resistant cells in the parental tumour [4],
presence of a mitochondrial adaptive response to TMZ
genotoxic stress [15] and dysregulation of glucose transporter
and drug metabolising enzymes [16]. To improve the clinical
efficacy of TMZ, we chose to identify molecular mechanisms
that confer resistance, and to target these molecules or path-
ways in order to re-sensitize the tumours to TMZ therapy.
Proteomics may reveal such mechanisms by directly
addressing the functional effectors of cellular, disease and
treatment processes [17]. Over the last few years, there have
been a number of published studies on glioma proteomics,
including analysis of patient biopsy samples [18, 19], body
fluids [20, 21], glioma cell lines [22, 23] and animal glioma
models [24]. However, to our knowledge, none of these
previous studies addressed the issue of TMZ resistance in
glioma cells. Therefore, the aim of this study is to identify, by
means of proteomics analysis, dysregulated protein candi-
dates that may potentially be involved in the onset of TMZ
resistance in human malignant gliomas. We firstly developed
TMZ-resistant variants of human glioma cell lines. Protein
expression changes associated with acquisition of TMZ
resistance were evaluated by two-dimensional gel electro-
phoresis coupled with mass spectrometry (MS). We sur-
mised that this approach would identify molecules that are
associated with TMZ resistance in malignant gliomas. Our
findings may have important implications for the develop-
ment of novel treatment strategies aimed at improving the
clinical efficacy of TMZ.
Materials and methods
Tissue samples
Patients included in this study are ethnic Chinese with
either low- or high-grade glioma. A total of 14 resected
tissues were included in this study. Prior to analysis, the
histological classification for all tissues was confirmed
according to the World Health Organization (WHO) brain
tumour classification system [25].
Cell lines and culture conditions
Human malignant glioma cell lines, D54-MG (GBM, a gift
from Dr. Darell D. Bigner, Duke University Medical Center,
USA) and U87-MG (GBM, obtained from American Type
Tissue Collection, Manassas, VA, USA), were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (1:1)
and minimum essential medium (MEM)-a, respectively
(GIBCO; Life Technologies, Inc., Carlsbad, CA, USA).
These media were supplemented with 10% heat-inactivated
foetal bovine serum (FBS) (GIBCO), 100 IU/ml penicillin
and 100 lg/ml streptomycin (GIBCO). Temozolomide
(TEMODAL) was obtained from Schering-Plough Co. Ltd.
(Kenilworth, NJ, USA). Stock solutions were prepared in
dimethyl sulphoxide (DMSO) at concentration of 10 mM
and diluted in the cell culture medium to the final
concentration.
The parental cell lines D54-MG and U87-MG, desig-
nated respectively as D54-C0 and U87-C0, were initially
exposed to 100 lM TMZ for 2 weeks, and their resistant
clones were isolated. These resistant clones were then
repeatedly exposed to IC50 of TMZ for a period of
12 months. This procedure mimicked the clinical regimen
of pulse-treatment method and ensured that the most
resistant clones were selected. Acquired TMZ resistance
was confirmed by sulforhodamine B (SRB) assay. Aliquot
of cells was isolated monthly and maintained in low dose
(100 lM) of TMZ. TMZ-resistant variants so generated
were denoted according to the number of months of drug
treatment (e.g. D54-P10 for cells isolated after 10 months
of treatment). Both the parental (D54-C0 and U87-C0) and
the passage controls (D54-C10 and U87-C6), which were
not exposed to TMZ, were included for parallel analysis.
In vitro chemo-sensitivity assay
For the chemo-sensitivity assay, 5,000 cells/well were
seeded in 96-well plates at 37C with 5% CO2. After 24 h,
the culture media were replaced with fresh media in the
absence or presence of serial concentrations of TMZ. After
96 h, the sulforhodamine B (SRB) assay (Sigma-Aldrich,
Saint Louis, MO, USA) was used to determine the sur-
viving cell numbers as measured by absorbance (optical
density, OD) at 490 nm. Results are expressed as the per-
centage of viable cells relative to the controls (cells without
prior TMZ treatment). A dose-response curve was plotted,
and IC50 values were calculated by derivation of the best-fit
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line, using three independent experiments performed in
triplicate.
TUNEL assay
Apoptotic cells were determined using the in situ cell death
detection kit POD (Roche Diagnostics, Indianapolis, IN,
USA), according to the manufacturer’s protocol. This assay
quantitatively determines DNA fragmentation at the free
30-OH termini catalysed by the terminal deoxyribonucleot-
idyl transferase (TdT). Apoptotic indices were obtained by
averaging the number of apoptotic cells within each of 10
randomly selected fields of view under light microscopy.
In vitro cell proliferation assay
5,000 cells/well were seeded in 96-well plates. Cells were
serum-starved for 1 day and retreated with serum in med-
ium before the experiment started. The relative density of
cells was determined by the SRB assay on a daily basis for
5 days. Absorbance was measured at 490 nm in three
independent experiments performed in triplicate.
Wound healing and adhesion assays
Wound healing assay was performed to assess cell migra-
tion. Assayed cells were grown to 100% confluency before
a wound was created on the cell monolayer using a 10-ll
pipette tip. Cell migration was then determined based on
the movement of cells towards the created lesion. The
closure of wound was observed after 12 and 18 h under
light microscopy. For the adhesion assay, 2 9 105/ml cells
in 100 ll were assayed by plating in triplicate in 96-well
plates which were pre-coated with 5 lg/ml collagen I
(Invitrogen, Carlsbad, CA, USA). Cell attachment was
determined 1 h after seeding. Attached cells were fixed in
4% paraformaldehyde at room temperature for 15 min and
stained with 5 mg/ml crystal violet (Accu-Chem Labora-
tories, Richardson, TX, USA) for 15 min. The purple
crystals formed were dissolved in 20% sodium dodecyl
sulphate (SDS; USB Corporation, Cleveland, OH, USA)
for 30 min, and absorbance was measured at 570/655 nm.
Cell cycle analysis
Assayed cells (1 9 106) were harvested during the expo-
nential growth phase. These cells were washed with
phosphate-buffered saline (PBS), fixed in 80% ethanol and
stored at -20C overnight. After fixation, cells were
washed twice with 1% FBS in PBS and resuspended in
PBS solution containing and resuspended in FACS solution
containing 200 lg RNase A (Sigma-Aldrich) and 1 lg
propidium iodide (Invitrogen). The reaction was incubated
in dark at 37C for 30 min before analysis on CytomicsTM
FC 500 flow cytometer (Beckman Coulter, Inc., Brea, CA,
USA).
Two-dimensional gel electrophoresis (2-DE) analysis
Cell pellets of TMZ-treated and untreated samples were
solubilised in 0.1 ml 40 mM Tris supplemented with
20 lg/ml RNase A (bovine pancreas source; USB Corpo-
ration), 50 U/ml DNase I (bovine pancreas source; USB
Corporation), complete ethylenediamine tetraacetic acid
(EDTA)-free protease inhibitors (Roche Diagnostics) and
0.5 mM phenylmethylsulphonylfluoride (PMSF) (USB
Corporation), and lysed by vortexing. After centrifugation
at 16,000g, the pellets were resuspended by vortexing in
0.1 ml extraction solution containing 8 M urea, 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulphonate
(CHAPS), 40 mM Tris, 0.2% carrier ampholytes and
2 mM tributyl phosphine (these reagents were included in
ReadyPrep sequential extraction kit; Bio-Rad, Hercules,
CA, USA). After centrifugation at 16,000g for 60 min at
4C, the supernatant was harvested as total protein lysates.
The concentrations of these lysates were quantified using
PlusOne 2-DE Quant kit (GE Biosciences, Buckingham-
shire, England). Proteins from each sample were subjected
to 2-DE as previously described [26, 27]. Briefly, 60 lg
protein lysate was diluted in 200 ll sample buffer and
applied on an 11-cm (pH 4–7) linear immobilized pH
gradient (IPG) Immobiline dry strip (GE Biosciences) for
first-dimension separation. In-sample active rehydration
was performed, and samples were subjected to isoelectric
focussing on IPGphor system (GE Biosciences). The same
conditions were used as previously described [26, 28].
After equilibration, protein was electrophoresed on a
12.5% precast EttanTM DALT gel (GE Biosciences) for
second-dimension separation. The resulting gels were sil-
ver stained, dried and captured using GS-800 calibrated
densitometer (Bio-Rad). Gel spots were detected, matched
and normalised using PDQuestTM 2-DE analysis software
(Bio-Rad), according to the manufacturer’s protocol. To
enhance the high reproducibility of our data and improve
consensus across triplicates gels, a group consensus tool
was used. The volume of each gel spot was employed as an
indicator of protein expression. The intensity of each spot
was normalised by total valid spot volume, and is reported
in parts per million (ppm). Student’s t-test was used to
analyse variance of spot intensities in controls (parental
cells and passage controls) and different TMZ-resistant
sublines. For selecting protein spots for identification, only
spots with significant expression difference (P \ 0.05) in
controls when compared with the TMZ-resistant variants as
well as those which have shown correlation to their IC50 of
TMZ were chosen for MS analysis.
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Protein identification by MALDI-TOF/TOF
Protein spots of interest were excised manually with syr-
inge needles, and the gel pieces were destained, washed,
equilibrated and dried before trypsin digestion (MS grade;
Promega, Madison, WT, USA) as previously described [26,
28]. Digestion was performed at 37C overnight, and
supernatants were pooled and purified using ZipTip pip-
ette tips (Millipore, Bedford, MA, USA). ABI 4800 pro-
teomics analyser matrix-assisted laser desorption/ionisation
time-of-flight (MALDI-TOF)/TOF (Applied Biosystems
Ltd., Foster City, CA, USA) operating in result-dependent
acquisition mode was used to generate the MS/MS spec-
trum data. A maximum of the five most intense tandem
mass spectra were collected for MS/MS, and the fragment
ion masses were compared with the NCBI/Swiss-Prot
database for protein identification using MASCOT version
2.1 (Matrix Science Inc., Boston, MA, USA).
Real-time quantitative polymerase chain reaction
(qPCR)
Total RNA extracted from the parental controls and resis-
tant counterparts were subjected to validation by qPCR.
Purified RNA (1 lg) was reverse-transcribed to comple-
mentary DNA (cDNA) using TaqMan reverse-transcription
reagents (Applied Biosystems Ltd.), following the manu-
facturer’s protocol. cDNA was then mixed with gene-spe-
cific primers (Supplementary Table 1) and Platinum
SYBR Green qPCR SuperMix-UDG with ROX (Invitro-
gen), and gene amplification was carried out in ABI Prism
7900HT sequence detection system (Applied Biosystems
Ltd.). Messenger RNA (mRNA) expression levels of each
gene after normalisation to b-actin as internal control are
expressed in relative fold ratios.
Results
Successful establishment of TMZ-resistant D54-MG
We successfully established a TMZ-resistant glioma cell
model for proteomics analysis. Two resistant sublines,
namely D54-P5 and D54-P10, were generated after treat-
ment with TMZ for 5 and 10 months, respectively. The two
resistant variants showed strong resistance to further TMZ
treatment. When compared with their control counterparts,
namely the parental line (D54-C0; IC50, 544.6 lM) and the
passage control line (D54-C10; IC50, 520.7 lM), D54-P5
and D54-P10 showed *2-fold (IC50, 1,251.2 lM; P =
0.046) and *3-fold (IC50, 1,681.7 lM; P = 0.004)
increase in their IC50 of TMZ, respectively (Figure 1a).
To investigate whether the increase in TMZ resistance in
glioma cells was associated with apoptosis, the numbers of
apoptotic cells were compared between TMZ-sensitive
(D54-C0) and TMZ-resistant (D54-P10) cells under dif-
ferent concentrations of TMZ (Figure 1b). Compared with
D54-C0 cells, D54-P10 cells showed a significant decrease
in the number of apoptotic cells (P \ 0.05) when treated
with 250 lM TMZ. At 500 lM and 1,000 lM TMZ
(P \ 0.01), the difference was even more pronounced, with
a 5-fold difference in cell apoptosis (Fig. 1b). These results
suggested a link between the onset of TMZ resistance and
reduction in apoptosis.
Cell properties after acquisition of TMZ resistance
Long-term in vitro treatment of D54-C0 cells with TMZ
was associated with a change in cell morphology. D54-P10
cells became more elongated, asymmetric and spike-like,
with more varied size and shrinkage of the cytoplasm.
Moreover, most of the D54-P10 cells exhibited pseudo-
podia and cytosolic granules (Fig. 2a). Besides, TMZ-
resistant D54-P10 demonstrated a lower proliferation rate
than TMZ-sensitive D54-C0 and D54-C10 (Fig. 2b).
Chemotherapeutic agents typically target rapidly dividing
cells, and are likely to be ineffective against slow-prolif-
erative and/or quiescent cancer cells. Thus, this population
(D54-P10) may indeed represent a subtype of cells that are
resistant to TMZ. In fact, acquired resistance to chemo-
therapeutic drugs is often associated with an increase in
malignant behaviour in cancer cells, because strong resis-
tance can facilitate progression and invasion of cancer
cells. The D54-P10 resistant subline also showed enhanced
cell adhesion and migration capacities when compared
with controls (Fig. 2c, d). Figure 2c demonstrates that
D54-P10 cells had an almost 2-fold increase in cell adhe-
sion (**P \ 0.01). Faster wound closure time was also
observed in D54-P10 cells when compared with both D54-
C0 and D54-C10 controls at 12 h (Fig. 2d).
Temozolomide is known to induce cell cycle arrests
[29]. Hence, we examined whether alterations of cell cycle
arrest were involved in the development of TMZ resis-
tance. By means of flow cytometry and western blotting,
the acquisition of TMZ resistance in D54-P10 cells was
found to be associated with accumulation of cells at G0/G1
from 71.93% (D54-C0) or 68.67% (D54-C10) to 87.88%
(D54-P10), and a decrease of cells in G2/M from 21.06%
(D54-C0) or 19.23% (D54-C10) to 7.29% (D54-P10)
(Fig. 2e). For the differential expression of cell cycle reg-
ulators, a higher level of cyclin B1, which is the regulatory
subunit of the M phase promoting factor, was found in
D54-P10 cells when compared with the controls. Inversely,
lower levels of cyclin D1 and cyclin-dependent kinase 4
(CDK4), which are known to play important roles in the
92 J Neurooncol (2012) 107:89–100
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G1/S cell cycle checkpoint, were found in D54-P10 cells,
suggestive of G1 phase arrest through inhibition of these
proteins (Fig. 2f). These findings indicate that onset of
TMZ resistance is mediated through loss of cell cycle
check points and changes in programmed cell death.
Proteins involved in TMZ resistance
We examined the protein profiles in four cell lines—the
two TMZ-resistant sublines (D54-P5 and D54-P10) and the
parental (D54-C0) and passage (D54-C10) controls and
looked for proteins that were differentially expressed.
Comparisons of protein spots on gels revealed 98 protein
spots that varied with significant differences (P \ 0.05).
Amongst these spots, 10 were verified to be valid protein
spots with ppm greater than 1,000, and relative fold ratios
that significantly correlated (P \ 0.05) with the IC50 of
TMZ of the treated cells. Importantly too, the spots were
successfully verified by manual inspection. Of the 10
protein spots chosen for MS/MS, 9 were successfully
identified. Figure 3 is a representative 2-DE gel showing
the respective locations of these protein spots whose
expressions varied within the 99th confidence level based
on the variance of mean changes. The results of MS/MS
and the detailed characterisation of the MS/MS data are
presented in Table 1. The protein score, total ion score,
confidence interval (CI, %), matched peptides and
sequence coverage are reported for each assigned protein.
In addition, the exact molecular weights and isoelectric
points for these proteins mostly matched with those
observed on the gel for each spot in question, providing
additional verification of their identities. Individual mass
spectrum of each protein is presented in Supplementary
Fig. 1. In some instances, more than one protein spot was
identified to be the same protein, suggesting the existence
of post-translation modifications, degradation, or alterna-
tive splicing isoforms in these proteins. As a result, these
nine spots actually referred to seven distinct proteins with
higher expressions in resistant glioma cells (D54-P5 and
D54-P10) than in the control lines (D54-C0 and D54-C10).
The functions of these proteins and their respective
expression ratios in each cell line are presented in Table 2.
Besides, in order to enhance the reliability of our data, we
performed Spearman’s rho correlation analysis between the
raw intensities of each spot on the gels and the sample’s
IC50 values. Results showed that, among the nine protein
spots, three proteins (SSP 2601, SSP3213 and SSP3506)
exhibited expressions that were strongly correlated with the
IC50 values (P \ 0.01, correlation coefficient [0.9). Others
(SSP0308, SSP1608, SSP3403, SSP4514, SSP5428 and
SSP5536) also demonstrated an association, showing cor-
relation coefficient values [0.5.
Fig. 1 Development of TMZ-resistant D54-MG malignant glioma
cells. a Survival curves of D54-C0 (parental D54-MG), D54-C10
(passage control, 10 months in culture), D54-P5 (TMZ-resistant
variant, 5 months in culture) and D54-P10 (TMZ-resistant variant,
10 months in culture) cells, determined by drug sensitivity assay. IC50
of TMZ of each cell lines is tabulated underneath the graph.
b Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay revealed more D54-C0 cells undergoing apoptosis
when compared with its resistant D54-P10 counterpart after treatment
with TMZ at different concentrations for 96 h. The above represen-
tative images show treatment of both D54-C0 and D54-P10 cells with
500 lM TMZ. Data were analysed by Student’s t-test and are
reported as mean ± standard deviation (SD). *P \ 0.05; **P \ 0.01
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For further validation, the transcript expression of six out
of these seven targets, including proliferating cell nuclear
antigen (PCNA), vimentin (VIM), cathepsin D (CTSD),
prolyl 4-hydroxylase, beta polypeptide (P4HB), mannose
6-phosphate receptor binding protein 1 (M6PRBP1) and
ezrin (EZR), were subjected to qPCR analysis. In accordance
with the proteomic data, upregulated transcript expression of
these proteins was found to be associated with D54-P10 cells
when compared with D54-C0 cells (Fig. 4). These proteins
had previously been reported to be involved in tumoural
processes, such as cell cycle alteration, cell proliferation,
epithelial–mesenchymal transition (EMT), apoptosis and
cell transformation. To demonstrate that the higher expres-
sion of these proteins was not limited to one particular cell
line, their expression in another pair of TMZ-sensitive (U87-
C0) and TMZ-resistant (U87-P6) malignant glioma cell lines
was also studied using qPCR. Higher expression of these
proteins was also found in U87-P6 resistant cells versus
Fig. 2 Alteration in morphology of D54-MG cells after acquisition of
TMZ resistance. a Images show the morphological appearance of
D54-C0, D54-C10 and D54-P10 cells under inverted microscope
(upper panel) and after haematoxylin and eosin staining (lower
panel). Original magnification, 9200. b Cell proliferation assay. D54-
C0, D54-C10 and D54-P10 cells were serum-starved before being
assayed for cell viability and growth using SRB assay. Cells were
retreated with serum in medium before the measurement was started.
Data were analysed by Student’s t-test and are reported as
mean ± SD. *P \ 0.05; **P \ 0.01. c Cell adhesion assay was
performed in D54-C0, D54-C10 and D54-P10 cells. Cell adhesive
capabilities of each type of cell are expressed as the fold ratio of the
number of adhered cells relative to the number of adhered D54-C0
cells. d Wound healing assay of D54-C0, D54-C10 and D54-P10 cells
was performed to assess the extent of cell migration towards the
artificially created wound. Images were taken at 12 and 18 h after
wound creation on the cell monolayer. At 12 h, D54-P10 cells
migrated faster towards the wound than D54-C0 and D54-C10 cells.
e Cell cycle analysis of D54-C0, D54-C10 and D54-P10 cells was
performed by flow cytometry. Long-term exposure to TMZ led to
cell cycle arrest of D54-P10 cells, such that more cells remained in
the G0/G1 phase. f Western blotting shows the levels of cell cycle
regulators, cyclin B1, CDK4 and cyclin D1, in D54-C0, D54-C10 and
D54-P10 cells. The images show representative results from triplicate
experiments
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U87-C0 sensitive cells (Fig. 4), and thus they resembled the
D54 cells. In particular, a 2-fold difference was found for
PCNA, CSTD and P4HB (**Fig. 4). These results indicate
that the proteins identified by our proteomics approach also
have corresponding upregulation of their gene expression
levels, and are associated with establishment of TMZ
resistance in glioma cells of different origins.
Upregulation of VIM, CTSD and P4HB in high-grade
glioma
To elucidate the clinical significance of these identified
proteins in human gliomas, three proteins (VIM, CTSD and
P4HB) were chosen for assessment in five low-grade and
nine high-grade glioma tissues. These proteins were chosen
for analysis mainly after the overall evaluation of their
relative fold ratios, MS scores and the degree of correlation
to the IC50 values. Overall, by Western blotting (Fig. 5a, b)
and immunohistochemical (IHC) staining (Fig. 5c), high
expression level of these proteins was found in high-grade
gliomas compared with low-grade tumours, and GBM,
which is the most malignant form of gliomas, revealed the
highest levels of expression, suggesting that these proteins
may be related to the malignant properties of glioma.
Discussion
Temozolomide has attracted considerable attention as an
effective chemotherapeutic agent against malignant glio-
mas. Although significant clinical benefits have been
achieved with the use of TMZ, patient outcomes remain
unsatisfactory, as acquired resistance commonly develops
and accounts for 90% of recurrent diseases [15]. Changes
in MGMT level [30], mismatch repair status [31, 32], loss
of p53 function [12] or activation of the Akt pathway [33]
have been identified as responsible for the development of
TMZ resistance. Despite extensive research, however, the
Fig. 3 Proteins associated with TMZ resistance in D54-P10 cells. A
representative 2-DE gel image shows the profile of total protein
extracted from D54-P10 cells. Nine proteins were recognised as spots
of interest and exhibited significant differential expression between
controls (D54-C0 and D54-C10) and resistant sublines (D54-P5 and
D54-P10) using Student’s t-test
Table 1 Differentially expressed proteins between sensitive and resistant D54-MG glioma cells identified by 2-DE and MALDI-TOF/TOF
analysis
Spot
number
Protein name Accession
number
Protein
score
Protein
score CI
(%)
Total
ion
score
Total ion
score CI (%)
Sequence
coverage
(%)
MWObs
(kDa)/pl
MWTh
(kDa)/pI
SSP0308 Proliferating cell nuclear
antigen
gil4505641 233 100 154 100 40 34/4.6 29/4.6
SSP1608 Vimentin gil340219 761 100 417 100 59 53/4.9 54/5.0
SSP2601 Vimentin gil340219 779 100 418 100 64 54/5.0 54/5.0
SSP3213 Cathepsin D gil157879202 120 99.9 70 99.8 31 27/5.1 27/5.1
SSP3403 Prolyl 4-hydroxylase, beta
polypeptide
gil62287145 348 100 236 100 30 45/5.0 57/4.7
SSP3506 Mannose 6-phosphate
receptor binding protein
1
gil255958282 418 100 332 100 35 47/5.3 47/5.3
SSP4514 Cytoplasmic actin gil82195535 591 100 454 100 47 43/5.5 42/5.3
SSP5428 Cytoplasmic actin gil1703118 85 99.9 55 99.8 18 41/5.6 42/5.3
SSP5536 Ezrin gil125987826 94 99.9 71 99.9 14 57/5.8 69/5.9
CI confidence interval, MWObs observed molecular weight, MWTh theoretical molecular weight
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mechanisms underlying acquired TMZ resistance are
incompletely characterised, and many biological processes
might exist independently of the aforementioned pathways.
Recently, Oliva et al. [15] reported that acquisition of
TMZ resistance may be associated with remodelling of
mitochondrial electron transport, whilst in Auger’s report,
resistance to TMZ was related to selection of pre-existent
resistant cells in the paternal tumour [4]. Although these
studies have improved our understanding of the develop-
ment of TMZ resistance in malignant gliomas, they were
mainly conducted at genomic and transcriptional levels. In
the present study, we took a step further to adopt a pro-
teomics approach, based on the principle that proteins are
the key structural and functional units in the body and are
the final products capable of translating information
between living cells. With our in vitro model, we demon-
strated that glioma cells tended to grow slowly and develop
significant changes in cell morphology after long-term
exposure to TMZ, suggestive of changes in cell cycle and
cytoskeleton regulation. Considering that proliferation
rates depend on cell cycle progression, slow-proliferating
cells may have lower activity of CDKs, which are critical
regulators of cell cycle progression. Our results showed G1
phase arrest together with reduction of CDK4 regulator in
the D54-P10 cell line, thus further reinforcing the reli-
ability of our findings. Moreover, TMZ resistance was
associated with increased adhesion and migration
capacities, indicating that onset of chemoresistance may
also promote cancer progression and other malignant
phenotypes. In fact, cell adhesion-mediated drug resistance
is thought to be a principal mechanism by which extra-
cellular matrix proteins provide a survival advantage
against cytotoxic drug-induced apoptosis [34]. We also
observed cell cycle alterations after the development of
TMZ resistance. It is of interest to note that, while previous
studies have suggested the association of cell cycle alter-
ations with p53 status [12], chk1- and chk2-mediated cell
death prevention [35] and Akt pathway activation bypass-
ing G2 arrest [33], none of the proteins identified in our
proteomics analysis are known to be involved in these
pathways.
Our study is the first to investigate and compare pro-
teomics profiling with regards to TMZ resistance in human
malignant glioma cells. We identified seven proteins
associated with TMZ resistance. By comparing the resis-
tant variants with not only the parental line but also the
passage controls, we confirmed that these changes in pro-
tein expressions were the results of long-term exposure to
TMZ rather than phenotypic changes following repeated
passaging. Furthermore, the observed alterations in protein
levels correlated well with changes in gene expressions.
There are several limitations to the present study. Our
in vitro model may not be fully representative of the highly
complex and heterogeneous in vivo microenvironment to
Table 2 Nine differentially expressed protein spots were identified; their functions, changes in relative fold ratio to controls and correlation
coefficient to the IC50 values are presented
Spot
number
Protein name Protein function Protein relative
expression (in fold ratio)
Correlation
coefficient
P value
D54-P5 D54-P10 IC50 values and protein
expression levels
Vs Vs
C0 C10 C0 C10
SSP0308 Proliferating cell nuclear antigen (PCNA) DNA replication 1.77 1.72 2.24 1.87 0.667 0.219
SSP1608 Vimentin (VIM) Cytoskeleton and cell
structure
3.31 2.92 3.51 4.00 0.821 0.089
SSP2601 Vimentin (VIM) Cytoskeleton and cell
structure
2.37 2.43 2.48 2.88 0.975 0.005**
SSP3213 Cathepsin D (CTSD) Protein biosynthesis 1.51 1.79 1.93 2.29 0.975 0.005**
SSP3403 Prolyl 4-hydroxylase, beta polypeptide
(P4HB)
Stress response and
chaperone activity
1.72 1.80 5.13 4.15 0.821 0.089
SSP3506 Mannose 6-phosphate receptor binding
protein 1 (M6PRBP1)
Transport 2.02 2.54 2.23 2.65 0.975 0.005**
SSP4514 Cytoplasmic actin Cytoskeleton and cell
structure
2.23 1.39 3.87 2.63 0.667 0.219
SSP5428 Cytoplasmic actin Cytoskeleton and cell
structure
2.86 2.06 3.72 2.63 0.667 0.219
SSP5536 Ezrin Anchor protein 1.32 1.23 2.20 1.90 0.667 0.219
* Spearman’s rho correlation test performed between D54 cell lines with different IC50 values and protein expression levels
** Correlation significant at 0.01 level (two-tailed); P \ 0.01
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which malignant gliomas are exposed. Although our model
was designed to mimic pulse treatment with TMZ, it may
differ from that found in a clinical setting due to the
influences of in vivo pharmacokinetics and pharmacody-
namics. Moreover, part of the clinical regimen currently
employed involves the use of concomitant irradiation,
which may alter cellular responses to TMZ. Although we
have verified our findings in two cell lines, it is uncertain
whether the same changes in protein expressions are uni-
versally present in all gliomas, which are now known to
belong to a heterogeneous group of neoplasms with dif-
fering cellular lineages, genetic changes, biological
behaviours and responses to chemotherapeutics.
Nevertheless, consistent with our observations of aug-
mented malignant behaviours after chronic exposure to
TMZ, several of the proteins (PCNA, VIM, CTSD, P4HB,
M6PRBP1 and EZR) identified in this study are known to
be associated with tumoural processes, such as cell cycle
alteration, cell proliferation, EMT, apoptosis and cell
transformation. For instance, PCNA is crucially involved in
several aspects of DNA metabolism, as well as cell cycle
regulation. It interacts with p21, which plays an essential
role in DNA damage responses by inducing cell cycle
arrest [36]. Moreover, B-cell lymphoma 2 (Bcl-2)-medi-
ated chemoresistance in prostate cancers has been shown to
be associated with an overexpression of PCNA that
Fig. 4 Gene expression of PCNA, VIM, CTSD, P4HB, M6PRBP1
and EZR in TMZ-sensitive and TMZ-resistant D54-MG and U87-MG
cells. qPCR was performed to investigate the gene expressions of
PCNA, VIM, CTSD, P4HB, M6PRBP1 and EZR in TMZ-sensitive
D54-C0 and U87-C0 cells and their respective TMZ-resistant
D54-P10 and U87-P6 counterparts. Data for each cell line are
presented as fold ratio relative to its respective control. Experiments
conducted in triplicate and repeated at least twice. Student’s t-test was
used to determine the level of significance. *P \ 0.05; **P \ 0.01
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counteracts the altered expression of cell cycle regulators
and controls cell cycle progression [37]. VIM is a type III
intermediate filament protein that is expressed frequently in
epithelial carcinomas and is correlated with tumour inva-
siveness and poor prognosis [38]. Upregulation of this
protein enhances carcinoma cell migration and adhesion,
which is in agreement with our findings. In malignant
glioma, a significant increase in VIM expression levels was
detected in cell cultures after treatment with a constant
concentration of TMZ [39]. CTSD affects multiple tumour
progression steps including proliferation, angiogenesis and
apoptosis [40]. In glioma, CTSD is a potential serum
marker of poor prognosis and is predictive of aggressive
tumour behaviour [41]. Expression of this protein in rela-
tion to chemo-response has been reported also in neuro-
blastoma, with the effect of protecting cells against
doxorubicin-induced cell death [42]. P4HB expression has
previously been reported to be related to the invasive
properties of malignant glioma. It is a chaperone protein
that mediates integrin-dependent cell adhesion and plays
important roles in cell invasion and migration [43]. ERp
57, a protein family member of P4HB, has previously been
reported to be involved in chemoresistance in ovarian
cancers [44]. These proteins have a range of functions
within the endoplasmic reticulum, one of which is pro-
tection against cell apoptosis in response to chemotherapy
[45]. M6PRBP1, also designated as cargo selection protein
(TIP47), was characterised as a cargo selection device for
mannose 6-phosphate receptors (MPRs) that directed their
transport from endosomes to the trans-Golgi network [46].
Recently, Hocsak’s group showed that TIP47 was able to
bind to mitochondria in oxidative stress, and inhibit mito-
chondrion-mediated cell death by protecting mitochondrial
membrane integrity [47]. Over-expression of TIP47 was
found to protect cells from taxol-induced cell death by
stabilising the mitochondrial membrane system and by
Fig. 5 Clinical significance of VIM, CTSD and P4HB in human
malignant glioma. a Representative blot images demonstrate high
expression levels of VIM, CTSD and P4HB in high-grade (HGG)
compared with low-grade gliomas (LGG). Glioblastoma reveals the
highest level of expression of the three proteins and is illustrated by
asterisk. b Whiskers (min to max) diagram shows the densitometry
data from Western blot analysis. Differences are expressed as ratio of
the target protein in different grade of glioma to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) density. c VIM, CTSD and
P4HB detection by IHC. Representative immunohistochemical stain-
ing of VIM, CTSD and P4HB in paraffin-embedded human glioma
tissues. Low-grade glioma tissues seen in b, d, f are weakly to
moderately stained, while in high-grade tissues, VIM, CTSD and
P4HB stainings are strongly intense (A, C, E). Original magnifica-
tion: 9100; 9400 (insets)
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favourably affecting the expression of Bcl-2 homologues,
suggesting that they may play important roles in the
development of resistance against cytostatic agents [48].
EZR is a linker between plasma membrane and actin
cytoskeleton, and can promote dissemination of tumour
cells [49]. Over-expression of EZR is associated with the
development of metastasis and poor outcome in osteosar-
coma [50]. In comparative proteomic study of paclitaxel-
resistant adenocarcinoma, overexpression of EZR was
hypothesised to inhibit induction of apoptosis through
activation of the Akt pathway [51].
In conclusion, our data show that long-term exposure to
TMZ may lead to the development of TMZ resistance and
the promotion of malignant phenotypes in human malig-
nant glioma cells. Proteomics is a feasible approach for the
identification of molecular candidates that may serve not
only as markers of chemoresistance but also as potential
therapeutic targets in the treatment of TMZ-resistant
human malignant gliomas. Whether our protein candidates
play roles in the development of TMZ resistance or simply
represent by-stander changes remains to be determined by
future work, including further in vivo studies and clinical
correlations. The present study provides a foundation for
future investigations on distinct protein candidates that
may contribute to the development of chemoresistance in
human malignant gliomas.
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